Alan Russell
Fortune : 799 344 $ au 31/05/2026
Fortune : 799 344 $ au 31/05/2026
Alan Russell is the founder of Edgewise Therapeutics, Inc., founded in 2017, where the title held is Director & Chief Scientific Officer.
Former jobs include Associate Director-Muscle Biology & Therapeutics at Cytokinetics, Inc. from 2002 to 2010, and VP & Head-Muscle Metabolism Discovery Performance at GlaxoSmithKline LLC from 2014 to 2017.
Education includes undergraduate and doctorate degrees from the University of Bath.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 23 400 ( 0,02 % ) | 799 344 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Fondateur | 01/01/2017 |
| Sociétés | Poste | Fin |
|---|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Directeur/Membre du Conseil | 01/09/2014 |
| CYTOKINETICS, INCORPORATED | Corporate Officer/Principal | 01/02/2010 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Cytokinetics, Inc.
Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
University of Bath
University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies for skeletal muscle diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national